<DOC>
	<DOCNO>NCT02743221</DOCNO>
	<brief_summary>The main purpose study evaluate progression-free survival ( PFS ) patient receive S 95005 + bevacizumab ( experimental arm ) capecitabine + bevacizumab ( control arm ) first-line treatment metastatic colorectal cancer patient non-eligible intensive therapy .</brief_summary>
	<brief_title>A Study Evaluating S 95005 Plus Bevacizumab Capecitabine Plus Bevacizumab Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible Intensive Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Written inform consent obtain . Male Female participant age â‰¥18 year old . Has ECOG performance status 0 , 1 2 time randomisation . Has definitive histologically cytologically confirm adenocarcinoma colon rectum . RAS status must determine ( mutant wild ) . Has least one measurable metastatic lesion . No previous anticancer therapy metastatic colorectal cancer . Previous adjuvant ( neoadjuvant patient rectal cancer ) chemotherapy allow complete 6 month start study treatment . Patient candidate combination chemotherapy irinotecan oxaliplatin , curative resection metastatic lesion . Is able take medication orally ( i.e. , feed tube ) . Has adequate organ function . Coagulation parameter normal limit ( therapeutic limit patient treat anticoagulant drug ) . Women childbearing potential must test negative serum pregnancy test . Female participant childbearing potential male participant partner childbearing potential must agree use highly effective method birth control . Women female partner use hormonal contraceptive must also use barrier method . Is willing able comply schedule visit study procedure . Foreseeable poor compliance study procedure . Is pregnant lactate female . Is inappropriate entry study judgment Investigator . Has certain serious illness serious medical condition ( ) describe protocol . Has certain recent treatment e.g . major surgery , field radiation , receive investigational agent , within specified time frame prior randomisation . Has previously receive S 95005 history allergic reaction attribute compound similar composition S 95005 excipients . Has rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . Has contraindication bevacizumab capecitabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>untreated</keyword>
	<keyword>first-line</keyword>
	<keyword>S95005</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>capecitabine</keyword>
</DOC>